Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® - US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial ...

On 3 April 2024, the Company announced publication of the results of the RED DESERT and SAHARA proof-of-concept studies, in the prestigious peer-reviewed journal European Journal of Heart Failure.

This comes after the US struck Houthi targets in Yemen on Saturday evening in what a US official described as a message to Iran. Information ...

This advertisement has not loaded yet, but your article continues below. NL youth facing three charges in relation to the death of a Pasadena woman’s dog A Pasadena woman is feeling a mixture of ...